Gene · 53637
Papers1,387
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
61 to 80 of 1,387
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Fasting reshapes tissue-specific niches to improve NK cell-mediated anti-tumor immunity. | Immunity | 2024 | 38878769 | PubTator, text mining | PubMed |
| ILC2s navigate tissue redistribution during infection using stage-specific S1P receptors. | bioRxiv | 2024 | 38798480 | PubTator, text mining | PubMed |
| The Current Landscape in the Development of Small-molecule Modulators Targeting Sphingosine-1-phosphate Receptors to Treat Neurodegenerative Diseases. | Curr Top Med Chem | 2024 | 38676503 | PubTator, text mining | PubMed |
| 1-Phosphate receptor agonists: A promising therapeutic avenue for ischemia-reperfusion injury management. | Int Immunopharmacol | 2024 | 38508097 | PubTator, text mining | PubMed |
| Siponimod Attenuates Neuronal Cell Death Triggered by Neuroinflammation via NFκB and Mitochondrial Pathways. | Int J Mol Sci | 2024 | 38473703 | PubTator, text mining | PubMed |
| Cytotoxic Tph subset with low B-cell helper functions and its involvement in systemic lupus erythematosus. | Commun Biol | 2024 | 38448723 | PubTator, text mining | PubMed |
| Etrasimod: First Approval. | Drugs | 2024 | 38388871 | PubTator, text mining | PubMed |
| Development and verification of a combined immune- and cancer-associated fibroblast related prognostic signature for colon adenocarcinoma. | Front Immunol | 2024 | 38312843 | PubTator, text mining | PubMed |
| Sphingosine 1-phosphate signaling axis mediates neuropeptide S-induced invasive phenotype of endometriotic cells. | FEBS J | 2024 | 38287231 | PubTator, text mining | PubMed |
| Personalized Use of Disease-Modifying Therapies in Multiple Sclerosis. | Pharmaceutics | 2024 | 38258130 | PubTator, text mining | PubMed |
| Emerging Oral Therapies for the Treatment of Psoriasis: A Review of Pipeline Agents. | Pharmaceutics | 2024 | 38258121 | PubTator, text mining | PubMed |
| The role of exhausted natural killer cells in the immunopathogenesis and treatment of leukemia. | Cell Commun Signal | 2024 | 38254135 | PubTator, text mining | PubMed |
| Circulating NK cells establish tissue residency upon acute infection of skin and mediate accelerated effector responses to secondary infection. | Immunity | 2024 | 38157853 | PubTator, text mining | PubMed |
| Fingolimod (FTY720), an FDA-approved sphingosine 1-phosphate (S1P) receptor agonist, restores endothelial hyperpermeability in cellular and animal models of dengue virus serotype 2 infection. | IUBMB Life | 2024 | 38031996 | PubTator, text mining | PubMed |
| Multiple sclerosis: time for early treatment with high-efficacy drugs. | J Neurol | 2024 | 37851189 | PubTator, text mining | PubMed |
| The Molecular Phenotype of Kidney Transplants: Insights From the MMDx Project. | Transplantation | 2024 | 37310258 | PubTator, text mining | PubMed |
| ENOX2 inhibition enhances infiltration of effector memory T-cell and mediates response to chemotherapy in immune-quiescent nasopharyngeal carcinoma. | J Adv Res | 2024 | 37061217 | PubTator, text mining | PubMed |
| [Siponimod (BAF312): General Characteristics and Clinical Implications of Pharmacogenomic Dosage in the Treatment of Active Secondary Progressive Multiple Sclerosis]. | Rev Med Chil | 2023 | 39093141 | PubTator, text mining | PubMed |
| Investigating the Mitoprotective Effects of S1P Receptor Modulators Ex Vivo Using a Novel Semi-Automated Live Imaging Set-Up. | Int J Mol Sci | 2023 | 38203434 | PubTator, text mining | PubMed |
| The role of sphingosine-1-phosphate in the development and progression of Parkinson's disease. | Front Cell Neurosci | 2023 | 38179204 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/53637/papers?page=4